A modified IRS-III chemotherapy regimen leads to prolonged survival in children with embryonal tumor with multilayer rosettes.

Hanson, Derek; Hoffman, Lindsey M; Nagabushan, Sumanth; Goumnerova, Liliana C; Rathmann, Allison; Vogel, Timothy; Ziegler, David S; Chi, Susan

Hanson, Derek; Hoffman, Lindsey M; Nagabushan, Sumanth; Goumnerova, Liliana C; Rathmann, Allison; Vogel, Timothy; Ziegler, David S; Chi, Susan.

Afiliação

Hanson D; Department of Pediatrics, Hackensack Meridian School of Medicine at Seton Hall University, Nutley, New Jersey, USA.
Hoffman LM; Department of Pediatrics, Joseph M. Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, New Jersey, USA.
Nagabushan S; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Goumnerova LC; Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Rathmann A; Sydney Children's Hospital, Randwick, New South Wales, Australia.
Vogel T; University of New South Wales, Sydney, New South Wales, Australia.
Ziegler DS; Trombo Protea, Inc., Weston, Massachusetts, USA.
Chi S; Department of Neurosurgery, Hackensack University Medical Center, Hackensack, New Jersey, USA.

Neurooncol Adv ; 2(1): vdaa120, 2020.

Article em En | MEDLINE | ID: mdl-33196040

Palavras-chave

brain tumor; chemotherapy; embryonal tumor with multilayer rosettes; pediatric

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Revista: Neurooncol Adv Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google